Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides

Bioorg Med Chem. 2017 Oct 1;25(19):5041-5049. doi: 10.1016/j.bmc.2017.02.063. Epub 2017 Feb 28.

Abstract

An important goal in the development of polo-like kinase 1 (Plk1) polo-box domain (PBD) binding inhibitors is selectivity for Plk1 relative to Plk2 and Plk3. In our current work we show that Plk1 PBD selectivity can be significantly enhanced by modulating interactions within a previously discovered "cryptic pocket" and a more recently identified proximal "auxiliary pocket."

Keywords: Cryptic binding pocket; Plk1; Polo-box domain; Selectivity.

MeSH terms

  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Cycle Proteins / chemistry
  • Cell Cycle Proteins / metabolism
  • Humans
  • Molecular Docking Simulation
  • Peptides / chemistry*
  • Peptides / pharmacology*
  • Polo-Like Kinase 1
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / chemistry
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins / chemistry
  • Proto-Oncogene Proteins / metabolism
  • Structure-Activity Relationship
  • Tumor Suppressor Proteins

Substances

  • Cell Cycle Proteins
  • Peptides
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Tumor Suppressor Proteins
  • PLK3 protein, human
  • PLK2 protein, human
  • Protein Serine-Threonine Kinases